E-NTPDase and E-ADA activities are altered in lymphocytes of patients with indeterminate form of Chagas' disease

Souza, Viviane do Carmo Gonçalves; Schlemmer, Karine Bizzi; Noal, Cristiano Bicca; Jaques, Jeandre Augusto dos Santos; Zimmermann, Carine Eloise Prestes; Leal, Cláudio A.M.; Fleck, Juliana; Casali, Émerson André; Morsch, Vera Maria; Schetinger, Maria Rosa Chitolina; Leal, Daniela Bitencourt Rosa

doi:10.1016/j.parint.2012.07.008

Cited by 24 publications

(11 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Taken together, these data suggest that the increased ecto-NTPDase and ADA activities in lymphocytes of hypertensive rats are occurring due to the activation of pro-inflammatory mediators. Alterations in purinergic system enzymes related to other diseases, such as lung cancer, Chagas' disease, experimental sepsis and multiple sclerosis, were already described in recent studies developed by our research group [27,40,44,45].…”

Section: Exercise Prevents Inflammatory Process In Hypertensionmentioning

confidence: 66%

“…The amount of protein was corrected in order to load a fixed concentration of protein (1 mg) in 12% SDS-PAGE, and it was determined on the basis of preliminary experiments by using different concentrations of proteins. Membranes were developed using the substrate of alkaline phosphatase, nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate [27].…”

Section: Exercise Prevents Inflammatory Process In Hypertensionmentioning

confidence: 99%

See 1 more Smart Citation

Swimming training prevents alterations in ecto-NTPDase and adenosine deaminase activities in lymphocytes from Nω-nitro-L-arginine methyl ester hydrochloride induced hypertension rats

Cardoso

Abdalla

Bagatini³

et al. 2015

Journal of Hypertension

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Exercise Prevents Inflammatory Process In Hypertensionmentioning

confidence: 66%

Section: Exercise Prevents Inflammatory Process In Hypertensionmentioning

confidence: 99%

Swimming training prevents alterations in ecto-NTPDase and adenosine deaminase activities in lymphocytes from Nω-nitro-L-arginine methyl ester hydrochloride induced hypertension rats

Cardoso

Abdalla

Bagatini³

et al. 2015

Journal of Hypertension

Self Cite

View full text Add to dashboard Cite

show abstract

“…25,26 In Chagas disease (caused by infection with the protozoan parasite Trypanosoma cruzi ) E-NTPDase 1 (CD39) and ectoadenosine deaminase activity are reduced in lymphocytes of patients with the disease. 74 Upregulation in CD39 is also implicated in the loss of purinergic vascular regulation in the colon during colitis. The resulting impaired regulation of GI blood flow may have contributed to a more compromised permeability barrier provided by epithelial cells lining the gut mucosa.…”

Section: 0 Adenosinergic Drugsmentioning

confidence: 99%

Potential for Developing Purinergic Drugs for Gastrointestinal Diseases

Ochoa-Cortés¹,

Liñán-Rico²,

Jacobson³

et al. 2014

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

Treatments for IBD, IBS, FD or motility disorders are not adequate, and purinergic drugs offer exciting new possibilities. GI symptoms that could be targeted for therapy include visceral pain, inflammatory pain, dysmotility, constipation and diarrhea. The focus of this review is on potential for developing purinergic drugs for clinical trials to treat GI symptoms. Purinergic receptors are divided into adenosine P1 (A1,A2A,A2B,A3), ionotropic ATP-gated P2X ion channel (P2X1–7) or metabotropic P2Y1,2,4,6,11–14 receptors. There is good experimental evidence for targeting A2A, A2B, A3, P2X7, P2X3 receptors or increasing endogenous adenosine levels to treat IBD, inflammatory pain, IBS/visceral pain, inflammatory-diarrhea and motility disorders. Purine genes are also potential biomarkers of disease. Advances in medicinal-chemistry have an accelerated pace toward clinical trials: Methotrexate and sulfasalazine, used to treat IBD, act by stimulating CD73-dependent adenosine production. ATP protects against NSAID-induced enteropathy and has pain-relieving properties in humans. A P2X7R antagonist AZD9056 is in clinical trials for CD. A3 AR drugs target inflammatory diseases (e.g. CF101; CF102). Dipyridamole, a nucleoside uptake-inhibitor, is in trials for endotoxemia. Drugs for pain in clinical-trials include P2X3/P2X2/3(AF-219) and P2X7(GSK1482160) antagonists and A1(GW493838) or A2A(BVT.115959) agonists. IberogastR is a phytopharmacon targeting purine-mechanisms with efficacy in IBS and FD. Purinergic drugs have excellent safety/efficacy profile for prospective clinical trials in IBD, IBS, FD and inflammatory-diarrhea. Genetic polymorphisms and caffeine consumption may affect susceptibility to treatment. Further studies in animals can clarify mechanisms and test new-generation drugs. Finally, there is still a huge gap in our knowledge of human pathophysiology of purinergic signaling.

show abstract

“…Little is known about the neurotransmitters most affected in Chagas disease, but there are hints that purinergic signalling might be impaired and there is evidence for a preferential destruction of intrinsic inhibitory neurons [ [389] are present in T. cruzi, which rapidly break down extracellular nucleotides. E-NTPDase (CD39) and ectoadenosine deaminase activity are decreased in lymphocytes of patients with the indeterminate form of Chagas disease [637]. Regulation of these extracellular nucleotides through ectonucleotidase activities on the platelets of patients with the indeterminate form of Chagas disease represents control of purine-mediated thrombogenic function in the cardiovascular system [636].…”

Section: Chagas Diseasementioning

confidence: 99%

Purinergic signalling in the gastrointestinal tract and related organs in health and disease

Burnstock

2013

Purinergic Signalling

View full text Add to dashboard Cite

Purinergic signalling plays major roles in the physiology and pathophysiology of digestive organs. Adenosine 5′-triphosphate (ATP), together with nitric oxide and vasoactive intestinal peptide, is a cotransmitter in nonadrenergic, non-cholinergic inhibitory neuromuscular transmission. P2X and P2Y receptors are widely expressed in myenteric and submucous enteric plexuses and participate in sympathetic transmission and neuromodulation involved in enteric reflex activities, as well as influencing gastric and intestinal epithelial secretion and vascular activities. Involvement of purinergic signalling has been identified in a variety of diseases, including inflammatory bowel disease, ischaemia, diabetes and cancer. Purinergic mechanosensory transduction forms the basis of enteric nociception, where ATP released from mucosal epithelial cells by distension activates nociceptive subepithelial primary afferent sensory fibres expressing P2X3 receptors to send messages to the pain centres in the central nervous system via interneurons in the spinal cord. Purinergic signalling is also involved in salivary gland and bile duct secretion.

show abstract

E-NTPDase and E-ADA activities are altered in lymphocytes of patients with indeterminate form of Chagas' disease

Cited by 24 publications

References 45 publications

Swimming training prevents alterations in ecto-NTPDase and adenosine deaminase activities in lymphocytes from Nω-nitro-L-arginine methyl ester hydrochloride induced hypertension rats

Swimming training prevents alterations in ecto-NTPDase and adenosine deaminase activities in lymphocytes from Nω-nitro-L-arginine methyl ester hydrochloride induced hypertension rats

Potential for Developing Purinergic Drugs for Gastrointestinal Diseases

Purinergic signalling in the gastrointestinal tract and related organs in health and disease

Contact Info

Product

Resources

About